Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07259304

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

This longitudinal observational study examines how social health, including social support, social roles, loneliness, social anxiety, and social network characteristics, relates to physical activity, sedentary time, and quality of life among ethnically and racially diverse adolescent and young adult (AYA) cancer patients aged 18-39 years. The study follows participants over four clinically significant timepoints in the first 12 months after diagnosis (baseline near diagnosis, mid treatment, near end of treatment, and 12 month follow up). At each timepoint, patients complete questionnaires and wear a wrist worn accelerometer for one week.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Anatomic Stage I Breast Cancer AJCC v8 Adenocarcinoma Adnexal Diseases Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Bone Diseases Bone Neoplasms Brain Diseases Brain Neoplasms Carcinoma Carcinoma, Medullary Carcinoma, Neuroendocrine Central Nervous System Diseases Central Nervous System Neoplasm Central Nervous System Neoplasms Clinical Stage I Cutaneous Melanoma AJCC v8 Clinical Stage IA Cutaneous Melanoma AJCC v8 Clinical Stage IB Cutaneous Melanoma AJCC v8 Clinical Stage II Cutaneous Melanoma AJCC v8 Clinical Stage IIA Cutaneous Melanoma AJCC v8 Clinical Stage IIB Cutaneous Melanoma AJCC v8 Clinical Stage IIC Cutaneous Melanoma AJCC v8 Clinical Stage III Cutaneous Melanoma AJCC v8 Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Gastrointestinal Diseases Gastrointestinal Neoplasms Genital Diseases Genital Diseases, Female Genital Diseases, Male Genital Neoplasms, Female Genital Neoplasms, Male Gonadal Disorders Hemic and Lymphatic Diseases Hodgkin Disease Hodgkin Lymphoma Immune System Diseases Immunoproliferative Disorders Intestinal Diseases Intestinal Neoplasms Lymphatic Diseases Lymphoma Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Male Urogenital Diseases Malignant Bone Neoplasm Malignant Brain Neoplasm Malignant Solid Neoplasm Malignant Testicular Neoplasm Musculoskeletal Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Nervous System Diseases Nervous System Neoplasms Neuroectodermal Tumors Neuroendocrine Tumors Non-Hodgkin Lymphoma Ovarian Diseases Ovarian Neoplasms Pathologic Stage I Cutaneous Melanoma AJCC v8 Pathologic Stage IA Cutaneous Melanoma AJCC v8 Pathologic Stage IB Cutaneous Melanoma AJCC v8 Pathologic Stage II Cutaneous Melanoma AJCC v8 Pathologic Stage IIA Cutaneous Melanoma AJCC v8 Pathologic Stage IIB Cutaneous Melanoma AJCC v8 Pathologic Stage IIC Cutaneous Melanoma AJCC v8 Pathologic Stage III Cutaneous Melanoma AJCC v8 Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Pathologic Stage IIID Cutaneous Melanoma AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Rectal Diseases Stage I Cervical Cancer AJCC v8 Stage I Colorectal Cancer AJCC v8 Stage I Differentiated Thyroid Gland Carcinoma AJCC v8 Stage I Ovarian Cancer AJCC v8 Stage I Thyroid Gland Medullary Carcinoma AJCC v8 Stage I Uterine Corpus Cancer AJCC v8 Stage IA Cervical Cancer AJCC v8 Stage IA Ovarian Cancer AJCC v8 Stage IA Uterine Corpus Cancer AJCC v8 Stage IA1 Cervical Cancer AJCC v8 Stage IA2 Cervical Cancer AJCC v8 Stage IB Cervical Cancer AJCC v8 Stage IB Ovarian Cancer AJCC v8 Stage IB Uterine Corpus Cancer AJCC v8 Stage IB1 Cervical Cancer AJCC v8 Stage IB2 Cervical Cancer AJCC v8 Stage IC Ovarian Cancer AJCC v8 Stage II Cervical Cancer AJCC v8 Stage II Colorectal Cancer AJCC v8 Stage II Differentiated Thyroid Gland Carcinoma AJCC v8 Stage II Ovarian Cancer AJCC v8 Stage II Thyroid Gland Medullary Carcinoma AJCC v8 Stage II Uterine Corpus Cancer AJCC v8 Stage IIA Cervical Cancer AJCC v8 Stage IIA Colorectal Cancer AJCC v8 Stage IIA Ovarian Cancer AJCC v8 Stage IIA1 Cervical Cancer AJCC v8 Stage IIA2 Cervical Cancer AJCC v8 Stage IIB Cervical Cancer AJCC v8 Stage IIB Colorectal Cancer AJCC v8 Stage IIB Ovarian Cancer AJCC v8 Stage IIC Colorectal Cancer AJCC v8 Stage III Cervical Cancer AJCC v8 Stage III Colorectal Cancer AJCC v8 Stage III Differentiated Thyroid Gland Carcinoma AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Thyroid Gland Medullary Carcinoma AJCC v8 Stage III Uterine Corpus Cancer AJCC v8 Stage IIIA Cervical Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA Uterine Corpus Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Cervical Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIB Uterine Corpus Cancer AJCC v8 Stage IIIC Colorectal Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IIIC Uterine Corpus Cancer AJCC v8 Stage IIIC1 Uterine Corpus Cancer AJCC v8 Stage IIIC2 Uterine Corpus Cancer AJCC v8 Testicular Diseases Testicular Neoplasms Urogenital Diseases Urogenital Neoplasms Uterine Cervical Diseases Uterine Cervical Neoplasms Uterine Diseases Uterine Neoplasms

Age range

18 year–39 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Los Angeles General Medical Center, Los Angeles, California, United States

Loading trial locations.

About this study

PRIMARY OBJECTIVES:

I. Characterize trajectories of social health over the course of cancer treatment and into early survivorship; II. Investigate longitudinal and potentially reciprocal associations between social health and activity behaviors (physical activity and sedentary time) and their relationship to quality of life; III. Examine whether gender, race/ethnicity, socioeconomic status, and symptom burden moderate these associations.

OUTLINE:

Patients complete surveys over 40 minutes and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-39 years at cancer diagnosis.
  • Newly diagnosed (within past 3 months) with one of the following cancer types commonly seen in AYAs: testis, breast, thyroid, cervix, colorectal, brain/central nervous system, non Hodgkin lymphoma, uterine, melanoma, bones and joints, ovary, Hodgkin lymphoma, lung, or gastric cancer.
  • Stage I-IV for solid tumors (AJCC 8th edition TNM staging) or I-IV for lymphomas (Ann Arbor staging).
  • Receiving care at a participating USC affiliated hospital (USC Norris Comprehensive Cancer Center, Keck Hospital of USC, or Los Angeles General Medical Center) or MD Anderson Cancer Center.
  • Clinician assessed expected survival greater than 12 months at time of diagnosis.
  • Able to complete questionnaires and wear a wrist worn accelerometer.
  • English or Spanish speaking.

Exclusion criteria

  • Leukemia (excluded due to longer treatment duration and different care trajectory).
  • Primary language other than English or Spanish.
  • Cognitive or physical limitations that preclude completion of surveys or wearing an accelerometer.

Treatment and study plan

Medical Device Usage and Evaluation

Other

Wear an actigraph GT3X-BT accelerometer

Quality-of-Life Assessment

Other

Complete survey

Other names: Quality of Life Assessment

Survey Administration

Other

Complete survey

Primary outcomes

  1. Change in social role functioning

    Time frame: Baseline up to 1 year

    Assessed using the PROMIS Ability to Participate in Social Roles and Activities Short Form 4a, which measures limitations in participation in usual social roles and activities due to health (higher scores indicate better participation).

  2. Change in perceived emotional support

    Time frame: Baseline up to 1 year

    Assessed using the PROMIS Emotional Support Short Form 4a, which measures perceived availability of people who provide emotional support, such as care, understanding, and someone to listen (higher scores indicate more emotional support).

  3. Change in perceived informational support

    Time frame: Baseline up to 1 year

    Assessed using the PROMIS Informational Support Short Form 4a, which measures perceived availability of people who provide advice, information, and guidance (higher scores indicate more informational support).

  4. Change in perceived instrumental support

    Time frame: Baseline up to 1 year

    Assessed using the PROMIS Instrumental Support Short Form 4a, which measures perceived availability of people who provide practical help and assistance with tasks (higher scores indicate more instrumental support).

  5. Change in loneliness score

    Time frame: Baseline up to 1 year

    Assessed using the UCLA Loneliness Scale short form, which measures subjective feelings of loneliness and social disconnection (higher scores indicate greater loneliness).

  6. Change in social anxiety symptoms

    Time frame: Baseline up to 1 year

    Assessed using the Mini Social Phobia Inventory (Mini SPIN), a brief validated measure of social anxiety and fear of social interactions (higher scores indicate greater social anxiety).

  7. Change in social network density

    Time frame: Baseline up to 1 year

    Assessed using a study developed egocentric social network questionnaire in which participants list up to 10 important adult social contacts and indicate which contacts know each other; density is calculated as the proportion of possible ties that are present (higher values indicate a more densely connected network).

  8. Change in proportion of supportive social ties

    Time frame: Baseline up to 1 year

    Assessed using a study developed egocentric social network questionnaire that measures whether each named social contact provides social support and encouragement for physical activity; the outcome is the proportion of social ties providing support (higher values indicate a more supportive network).

  9. Change in frequency of social contact

    Time frame: Baseline up to 1 year

    Assessed using a study developed egocentric social network questionnaire that captures how often participants interact with each named social contact; the outcome is the average reported frequency of contact across alters (higher values indicate more frequent social contact).

  10. Change in total daily physical activity

    Time frame: Baseline up to 1 year

    Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Raw data are converted to monitor independent movement summary (MIMS) units, and total daily physical activity is represented by average daily MIMS units across valid wear days (higher values indicate more physical activity).

  11. Change in total daily sedentary time

    Time frame: Baseline up to 1 year

    Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Sedentary time is calculated from accelerometer data as average minutes per day spent in sedentary behavior (e.g., low movement periods while awake) across valid wear days (higher values indicate more sedentary time).

Secondary outcomes

  1. Change in Quality of Life

    Time frame: Baseline up to 1 year

    Patient reported quality of life using PROMIS Global Health 10, assessed at baseline and 12 month follow up.

  2. Symptom Burden

    Time frame: Baseline up to 1 year

    Symptom burden assessed using the MD Anderson Symptom Inventory (MDASI) at all four timepoints.

Sponsors and collaborators

Lead sponsor

University of Southern California

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors: A Longitudinal Study

Important dates

Study start
2021
Primary completion
2026
Study completion
2027
First posted
Dec 2, 2025
Registry last updated
Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.